On February 18, 2020 Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, reported that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences (Press release, Epizyme, FEB 18, 2020, View Source [SID1234554444]). Details of the events are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter and Full-Year 2019 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results on Monday, Feb. 24, 2020 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 9045277.

Upcoming Investor Conference Presentations: Management will present at the following upcoming conferences:
9th Annual SVB Leerink Global Healthcare Conference on Tuesday, Feb. 25, 2020 at 1:00 p.m. ET in New York City;
Cowen and Company’s 40th Annual Healthcare Conference on Monday, March 2, 2020 at 3:30 p.m. ET in Boston;
Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 2:05 p.m. ET in Miami; and,
Oppenheimer 30th Annual Healthcare Conference on Tuesday, March 17, 2020 at 3:55 p.m. ET in New York City.
Live webcasts will be available in the investor section of the company’s website at www.epizyme.com. The webcasts will be archived for 60 days following the call and presentations.

On February 18, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) reported it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market closes (Press release, Vanda Pharmaceuticals, FEB 18, 2020, View Source [SID1234554460]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vanda will host a conference call at 4:30 PM ET on Tuesday, February 25, 2020, during which management will discuss the fourth quarter and full year 2019 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 2149683.

The conference call will be broadcast simultaneously and archived on Vanda’s website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Tuesday, February 25, 2020, beginning at 7:30 PM ET and will be accessible until Tuesday, March 3, 2020, at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 2149683.

On February 18, 2020 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, reported that Bristol-Myers Squibb informed the company that the randomized Phase 2 trial testing the combination of cabiralizumab with Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer did not meet its primary endpoint (Press release, Five Prime Therapeutics, FEB 18, 2020, View Source [SID1234554429]). While Bristol-Myers Squibb has no near term plans for additional sponsored development of cabiralizumab, Bristol-Myers Squibb will continue to support the evaluation of cabiralizumab in select, ongoing investigator-sponsored trials and may continue to assess future development opportunities for the investigational asset. Bristol-Myers Squibb also informed the company that no new safety signals were observed in the Phase 2 trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Pancreatic cancer is a difficult disease to treat, and unfortunately the combination of cabiralizumab and Opdivo with and without chemotherapy did not show any meaningful benefit over standard of care chemotherapy in this randomized, controlled Phase 2 trial," said Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics. "We are disappointed by this outcome and appreciate the participation of the investigators, staff, patients, caregivers, and our development partner who all contributed to the conduct and completion of this Phase 2 clinical trial."

The multi-arm, randomized, controlled Phase 2 clinical trial (NCT03336216) enrolled approximately 160 patients with locally advanced or metastatic pancreatic cancer that has progressed during or after one line of chemotherapy.

On February 18, 2020 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, reported participation at the following upcoming conferences (Press release, Rocket Pharmaceuticals, FEB 18, 2020, View Source [SID1234554445]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

9th Annual SVB Leerink Global Healthcare Conference, New York, N.Y.
Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, February 25, 2020, at 10:30 a.m. Eastern Time.
Cowen’s 40th Annual Health Care Conference, Boston, M.A.
Gaurav Shah, M.D., President and CEO, is scheduled to present on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.
Annual Barclays Global Healthcare Conference, Miami, F.L.
Tuesday, March 10, 2020
Oppenheimer’s 30th Annual Healthcare Conference, New York, N.Y.
Gaurav Shah, M.D., President and CEO, is scheduled to present on Wednesday, March 18, 2020, at 11:30 a.m. Eastern Time
A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

On February 18, 2020 Nektar Therapeutics (Nasdaq: NKTR) reported that it will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February 27, 2020, after the close of U.S.-based financial markets (Press release, Nektar Therapeutics, FEB 18, 2020, View Source [SID1234554461]). Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: View Source The web broadcast of the conference call will be available for replay through March 27, 2020.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Conference ID: 2507828